.STUDY HIGHLIGHT.16 Oct 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to standard treatment for muscle-invasive bladder cancer cells strengthened event-free and also generally survival, marking a brand new treatment choice for this disorder.